Cryoport (CYRX) received a buy rating with a price target of $9.1, implying a 17% upside by fiscal year 2026. The company showed double-digit revenue growth in Q4 2025, driven by its Life Sciences Services segment, and improved gross margins to 47.8%. Management aims for positive adjusted EBITDA in the second half of 2026, supported by cost reductions and a stronger partnership with DHL. Risks include geopolitical volatility and rising logistics costs, but the company’s clinical pipeline and commercial transitions underpin a bullish outlook.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
UnitedHealth Group reported second-quarter earnings that surpassed expectations, driven by better management of high medical costs and AI investments to streamline operations. The company raised its 2026 adjusted earnings forecast to $19.50-$20 per s...
Meta Platforms has been upgraded to a buy rating due to its new cloud business, which is expected to stabilize cash flow and improve profitability. Despite heavy capital expenditures, Meta maintains strong free cash flow margins and operational effic...
Bitcoin Treasury Capital, a Stockholm-based firm, has received approval to issue 195,078 Class A preferred shares on the Spotlight Stock Market, starting July 20, 2026. These shares, priced at SEK 120 each, offer a 10% annual dividend backed entirely...
Bitcoin price recently hit a strong resistance level at $65,600 but failed to break through, signaling a possible reversal. Short-term momentum is weakening, suggesting the price may decline unless a sudden surge occurs. Key support levels include th...
